Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical ...

Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today ...

XYNGARI� Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America - SAN DIEGO, March 4, 2025 /PRNewswire/ -- Dermata Therapeutics, Inc. (Nasdaq: DRMA, ...

If you're dealing with consistent breakouts, especially around your jawline, chin, or lower cheeks, you might be battling ...

After a 15-year battle with persistent acne, countless medications, and expensive procedures, I've finally discovered a ...

AviClear is a safe, non-invasive, and long-term solution suitable for all skin types AviClear by Cutera is the first and only FDA-cleared laser treatment for mild, moderate, and severe acne ...

Located in Roslyn, House of Skin offers personalized, medically advanced treatments designed to deliver life-changing results ...

These dermatologist-recommended acne treatments can help manage teen acne. Find over-the-counter options including cleansers, spot treatments and more.

Interest in vitamin A is booming as Americans seek alternative treatments for measles. While the essential nutrient has a ...

“Hormonal changes increase oil production and disrupt cell turnover, creating an environment where acne-causing bacteria ...

Dermata Therapeutics (DRMA) announced that the last patient has completed their last visit in the company’s first pivotal Phase 3 Spongilla ...

It's a skin condition that affects almost everyone, popping up for a variety of reasons (and always at the most inconvenient ...